• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 27, 2018

View Archived Issues

Regulatory actions for April 26, 2018

Read More

Clinical data for April 26, 2018

Read More

Regulatory front

Concerned about the increasing uncertainty that exists about the patent-eligibility of biotech products that incorporate naturally occurring substances and methods of using those products in therapeutic, diagnostic or industrial processes, the Biotechnology Innovation Organization (BIO) submitted an amicus brief in Natural Alternatives Inc. v. Creative Compounds LLC, which is on appeal to the U.S. Court of Appeal for the Federal Circuit.  Read More

Financings

Innovent Biologics Inc., of Hong Kong, completed a $150 million series E round of financing. The round was led by Capital Group Private Markets with its $90 million investment.  Read More

Other news to note

Hesperos Inc., of Orlando, Fla., said it increased its human-on-a-chip drug testing capabilities by adding an in vitro, human-human neuromuscular model to its multi-organ microfluidic device systems. Abnormal function of the neuromuscular junction is associated with diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy. Read More

Reforms, market demand helping Chinese pharmas grow: FY2017 earnings

HONG KONG – Fiscal year 2017 was good for most Chinese pharmaceutical companies, with mainland-listed pharma shares gaining 11 percent in value. Read More

Medicinal chemistry lagging behind in the digital revolution

LONDON – In a digital world where protein structures can be solved in seconds and a human genome sequenced for $1,000, chemistry is stuck in an analogue past and restraining progress all around. Read More

Better pain drugs necessary part of opioid epidemic fight

LOS ANGELES – At the American Academy of Neurology (AAN) annual meeting this week, Walter Koroshetz pointed out two causes of the opioid epidemic that are obvious in one sense. But ending the opioid epidemic will require figuring out a way to address the relationship between them. Read More

Cross-border partnering propels China's biotech sector

SUZHOU, China – It is no secret that the fortunes of China's biotech sector have never looked brighter. There is a list of reasons – recent regulatory reforms, unwavering government financial support, vast amounts of venture capital, legions of young doctorates and a huge untapped market. But without cross-border partnering, China's biotech industry would look dramatically different. Read More

Alexion, Shire report earnings amid major transformations underway

Solid first-quarter earnings, positive phase III data on Soliris (eculizumab) successor ALXN-1210, and rosy revenue guidance sent shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) climbing Thursday as the company pushed ahead with efforts to rebuild its pipeline. It reported earnings of $1.68 per share, beating analyst expectations of $1.50. Read More

Adocia banks $50M on Tonghua Dongbao diabetes deal in China

DUBLIN – Shares in Adocia SA gained 27 percent Thursday on news of a diabetes deal in China with Tonghua Dongbao Pharmaceutical Co. Ltd., under which it will pocket $50 million up front with up to $85 million more to come in potential development milestones, as well as double-digit sales royalties. The agreement covers Biochaperone Combo, its fixed-ratio combination of basal insulin (insulin glargine) and prandial insulin (insulin lispro), as well as its fast-acting insulin formulation Biochaperone Lispro, in China and several other countries. Lyon, France-based Adocia retains rights to the U.S., Europe and Japan. It will also receive research funding from its new partner. Read More

ALS thwarts another contender as Neuraltus comes up short in confirmatory phase II

Privately held Neuraltus Pharmaceuticals Inc. reported Thursday that a confirmatory phase II study of its single candidate, NP-001, that enrolled 138 individuals with amyotrophic lateral sclerosis (ALS) who had elevated levels of systemic inflammation failed to meet its primary and secondary endpoints: change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score and in pulmonary function as measured by slow vital capacity (SVC) readings. Read More

Conference data: American Academy of Neurology (Los Angeles)

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe